Skip to content

Cohort study combined with omics screening for the early diagnostic markers in Crohn's disease

Cohort study combined with omics screening for the early diagnostic markers in Crohn's disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022728
Enrollment
Unknown
Registered
2019-04-23
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Gold Standard:Clinical outcome
microbes,&#32
imaging&#32
of&#32
clinical&#32
subclinical&#32
CD,&#32
combined&#32
with&#32
and&#32

Sponsors

The 7th Medical Center of the PLA General Hospital (Army general hospital)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with one of the high-risk conditions of CD were examined by colonoscopy. Once a single or multiple patients with shallow ulcers or erosions were found at the end of the ileum or in different parts of the colon, enrollment and follow-up were determined. High-risk conditions of CD including: patients with unexplained refractory chronic abdominal pain accompanied by changes in bowel habits (including diarrhea, constipation); those with no pain in the right lower quadrant after appendicitis; patients with frequent oral ulcers without cause; unexplained skin, Patients with joint disease; first-degree relatives with IBD; healthy physical examination found in patients with single or multiple aphthous ulcers at the end of the ileum or different parts of the colon.

Exclusion criteria

Exclusion criteria: 1. Diagnosed as advanced CD/ulcerative colitis (UC) or confirmed CD/UC patients are found in screening; 2. Identified patients with other immune diseases, such as Behcet's disease; 3. Combined with pathological considerations for lymph Tumors, suspected tumors and other diseases; 4. People with common intestinal infections (acute and chronic infection, including confirmed intestinal tuberculosis); 5. The intestinal damage caused by oral non-steroidal drugs within 3 months before colonoscopy ; 6. Patients with vascular disease ; 7. Patients with celiac disease; 8. Patients with complication of organ failure; 9. Patients who could not be examined or followed up.

Design outcomes

Primary

MeasureTime frame
serum marker;Biomarkers of intestinal flora;Metabolic marker;Pathological feature;

Secondary

MeasureTime frame
Imaging features;

Countries

China

Contacts

Public ContactJianqiu Sheng

The 7th Medical Center of the PLA General Hospital (Army general hospital)

jianqiu@263.net+86 13601187561

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026